安进

最新新闻

• 公司公告
  Amgen | 4: Statement of changes in beneficial ownership of securities-Officer Busch Matthew C.
  SEC · 2026/5/12
• Cantor Fitzgerald Maintains Amgen(AMGN.US) With Hold Rating, Raises Target Price to $440
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• 评级变动
  Scotiabank Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $500
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  Scotiabank Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $500
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  Truist Financial Maintains Amgen(AMGN.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 公司公告
  Amgen | 3: Initial statement of beneficial ownership of securities- Dittrich Thomas J.W.
  SEC · 2026/9/5
• Wells Fargo Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $435
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• 评级变动
  A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $380 to $457
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $430
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• 公司公告
  Amgen | 4: Statement of changes in beneficial ownership of securities-Officer Grygiel Nancy A.
  SEC · 2026/5/12
• 评级变动
  Goldman Sachs Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $450
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 公司公告
  Amgen | 4: Statement of changes in beneficial ownership of securities-Director Klotman Mary E.
  SEC · 2026/5/22
• 评级变动
  A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $317 to $457
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Amgen (AMGN) and BrightSpring Health Services, Inc. (BTSG)
  TipRanks · 2026/9/17
• 评级变动
  Scotiabank Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $450
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  Raymond James Maintains Amgen(AMGN.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• 评级变动
  Wells Fargo Maintains Amgen(AMGN.US) With Hold Rating, Raises Target Price to $435
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $457
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• UBS Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $470
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 公司公告
  Amgen | 4: Statement of changes in beneficial ownership of securities-Director Garland Greg C.
  SEC · 2026/5/22
• 评级变动
  Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $457
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $317 to $452
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  BMO Capital Downgrades Amgen(AMGN.US) to Hold Rating, Maintains Target Price $450
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• 评级变动
  Citi Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $405
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $452
  \u5e02\u573a\u8d44\u8baf · 2026/8/27

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。